Sorrentino M J
University of Chicago, Pritzker School of Medicine, IL, USA.
Postgrad Med. 1997 Jan;101(1):83-6, 89-90, 93-4. doi: 10.3810/pgm.1997.01.143.
The goals of therapy for congestive heart failure (CHF) are to improve quality of life and to prolong it. Improvement in patients with CHF can only be realized, however, if a multidisciplinary healthcare team can provide effective management in both the inpatient and outpatient settings. Inhibition of compensatory mechanisms that perpetuate CHF is the first step in achieving treatment goals. Combination therapy with diuretics, digoxin (Lanoxicaps, Lanoxin), and vasodilators is used for patients with symptomatic heart failure and volume overload. Because angiotensin-converting enzyme inhibitors improve survival rates more than other vasodilators, they are preferred in patients with systolic dysfunction.
充血性心力衰竭（CHF）的治疗目标是提高生活质量并延长寿命。然而，只有多学科医疗团队能够在住院和门诊环境中提供有效的管理，CHF患者的病情才能得到改善。抑制使CHF持续存在的代偿机制是实现治疗目标的第一步。对于有症状性心力衰竭和容量超负荷的患者，使用利尿剂、地高辛（Lanoxicaps、Lanoxin）和血管扩张剂的联合治疗。由于血管紧张素转换酶抑制剂比其他血管扩张剂更能提高生存率，因此它们是收缩功能障碍患者的首选药物。
